News
Sobi adds rare lymphoma drug with $580m Innate tie-up
Sobi chief executive Guido Oelkers is preparing his exit, but is still cutting deals, licensing a lymphoma drug from Innate for up to $580m.
News
Quartet of biotechs join Nasdaq after stellar IPOs
Braveheart Bio, Latigo Biotherapeutics, Attovia Therapeutics, and BlossomHill Therapeutics have finalised their Nasdaq listings, raising over $1.2bn.
News
TransThera's resistant biliary cancer drug cleared in China
TransThera's Yochanra has been cleared in China as the world's first drug that can overcome resistance to FGFR inhibitors in cholangiocarcinoma.
News
Third time lucky for Replimune as FDA OKs melanoma drug
At its third attempt, Replimune has finally won FDA approval for its advanced melanoma treatment RP1, now named Tudriqev and its first product.
News
LifeMine gets $263m for transplant drug, and other financing...
Recent biotech financings are headed by LifeMine's $263m for a transplant drug, with Expedition, Ratio, Vedanta, and Mironid also in on the action.
News
Views & Analysis
Deep Dive
Editor's Picks
Editor's Picks
